ADMA Biologics Inc (NASDAQ:ADMA) Given Consensus Rating of “Moderate Buy” by Analysts

ADMA Biologics Inc (NASDAQ:ADMA) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $18.6667.

ADMA has been the subject of a number of recent research reports. Canaccord Genuity Group cut their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Raymond James Financial started coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective on the stock. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Portnoy, Faruqi & Faruqi, and others, issued reminders about the upcoming lead-plaintiff deadline in the ADMA securities class action. Article Title
• Neutral Sentiment: Several reports repeated the allegation that ADMA’s reported revenue growth may have been inflated by channel stuffing, but these are legal claims rather than new company disclosures. Article Title
• Negative Sentiment: The securities-fraud lawsuit and the associated publicity create legal and reputational risk, which can weigh on sentiment until the case is resolved. Article Title

Insider Transactions at ADMA Biologics

In other news, Director Jerrold B. Grossman bought 12,500 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the purchase, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors have recently made changes to their positions in the company. Lido Advisors LLC grew its stake in shares of ADMA Biologics by 3.8% in the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after purchasing an additional 629 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of ADMA Biologics by 11.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock worth $117,000 after buying an additional 634 shares during the period. Cim LLC lifted its position in shares of ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after buying an additional 665 shares during the period. Smartleaf Asset Management LLC boosted its stake in ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 700 shares in the last quarter. Finally, Cerity Partners LLC grew its position in ADMA Biologics by 1.8% in the second quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock valued at $884,000 after acquiring an additional 869 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

ADMA opened at $8.59 on Wednesday. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $8.48 and its 200 day moving average price is $12.10. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of 12.63 and a beta of 0.73. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same period last year, the firm posted $0.11 EPS. ADMA Biologics’s quarterly revenue was down .3% compared to the same quarter last year. As a group, sell-side analysts expect that ADMA Biologics will post 0.8 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.